Prevalence of Small Intestinal Bacterial Overgrowth in Multiple Sclerosis: a Case-Control Study from China

Zhang, Yongbo; Guo-yi, Liu; Duan, Yuanli; Han, Xinwen; Dong, Huihua; Geng, Jia

doi:10.1016/j.jneuroim.2016.11.004

Cited by 14 publications

(9 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Likewise, gut microbiota have been linked to MetS components, and MetS occurs more often in patients with small intestinal bacterial overgrowth (SIBO) [32]. In this respect, SIBO is highly predominant in patients with MS, thereby possibly playing a potential role in MS pathophysiology [60]. Additionally, reports of gut microbiota composition differences between MS patients and healthy individuals have emerged [61,62], and specific pathways of the interaction between microbiota and neuroinflammation have started to be elucidated [63].…”

Section: Discussionmentioning

confidence: 99%

Impact of Body Mass Index on the Age of Relapsing-Remitting Multiple Sclerosis Onset: A Retrospective Study

Siokas

Katsiardanis

Aloizou

et al. 2021

Neurology International

View full text Add to dashboard Cite

A BACKROUND: Multiple sclerosis (MS) is a complex chronic disease of the central nervous system (CNS). Body mass index (BMI), a component of metabolic syndrome (MetS), is considered among the risk factors for MS. However, its role in MS remains ambiguous. OBJECTIVE: To examine the impact of BMI on the age of onset in patients with relapsing-remitting MS (RRMS) in a Greek cohort. METHODS: Data from 821 Greek patients with RRMS were collected. The BMI values were considered as quartiles. Comparisons for the demographic characteristics between the quartiles were made by Pearson’s chi-square test for the categorical variables and by ANOVA for the continuous variables. An overall p-value was calculated corresponding to trend for association. In case of significant association, further post-hoc analysis was performed in order to identify differences in demographic characteristics between specific BMI quartiles groups. Linear regression analyses were used to assess the relationship between BMI and age at onset of MS. RESULTS: Comparisons of participant characteristics by quartiles of BMI revealed that participants with the highest BMI had an older age of disease onset. Results from linear regression analysis showed that with each increase of 1 BMI unit, the age of RRMS onset increases by 0.255 (95% CI 0.136 to 0.374) years, p < 0.001. CONCLUSIONS: Patients with higher BMI, as a parameter of MetS, exhibit increased age of RRMS onset. Our results may present an alternative personalized approach for diagnosis, prognosis, and/or prevention of RRMS.

show abstract

Section: Discussionmentioning

confidence: 99%

Impact of Body Mass Index on the Age of Relapsing-Remitting Multiple Sclerosis Onset: A Retrospective Study

Siokas

Katsiardanis

Aloizou

et al. 2021

Neurology International

View full text Add to dashboard Cite

show abstract

“…The standard for SIBO diagnosis is the detection, on culture, of > 10 5 colony‐forming units of bacteria per ml of jejunal fluid obtained by direct aspiration of jejunal contents [ 73 ]. According to Zhang et al, SIBO is high prevalent in Chinese patients with MS (45 patients of 118 were SIBO positive) [ 74 ]. Moreover, the gastrointestinal symptoms, such as constipation, bloating, and faecal incontinence were common (78% of subjects; 46.6%; 44.1%; respectively) in these cases [ 74 ].…”

Section: Saccharomyces Boulardii Sibo and Ms—is There A LImentioning

confidence: 99%

“…According to Zhang et al, SIBO is high prevalent in Chinese patients with MS (45 patients of 118 were SIBO positive) [ 74 ]. Moreover, the gastrointestinal symptoms, such as constipation, bloating, and faecal incontinence were common (78% of subjects; 46.6%; 44.1%; respectively) in these cases [ 74 ]. It has been proven that some probiotic strains such as Lactobacillus acidophilus , Lactobacillus casei , Lactobacillus fermentum , and Bifidobacterium bifidum are effective in treating gastrointestinal symptoms observed in patients with MS.…”

Section: Saccharomyces Boulardii Sibo and Ms—is There A LImentioning

confidence: 99%

Saccharomyces boulardii CNCM I-745: A Non-bacterial Microorganism Used as Probiotic Agent in Supporting Treatment of Selected Diseases

Kaźmierczak-Siedlecka

Ruszkowski

Fic

et al. 2020

Curr Microbiol

View full text Add to dashboard Cite

The yeast Saccharomyces boulardii CNCM I-745 is a unique, non-bacterial microorganism classified as a probiotic agent. In this review article, at first, we briefly summarized the mechanisms responsible for its probiotic properties, e.g. adhesion to and elimination of enteropathogenic microorganisms and their toxins; extracellular cleavage of pathogens’ virulent factors; trophic and anti-inflammatory effects on the intestinal mucosa. The efficacy of S. boulardii administration was tested in variety of human diseases. We discussed the results of S. boulardii CNCM I-745 use in the treatment or prevention of Helicobacter pylori infections, diarrhoea ( Clostridium difficile infections, antibiotic-associated diarrhoea, and traveller’s diarrhoea), inflammatory bowel diseases, irritable bowel syndrome, candidiasis, dyslipidemia, and small intestine bacterial overgrowth in patients with multiple sclerosis. In case of limited number of studies regarding this strain, we also presented studies demonstrating properties and efficacy of other strains of S. boulardii. Administration of S. boulardii CNCMI I-745 during antibiotic therapy has certain advantage over bacterial probiotics, because—due to its fungal natural properties—it is intrinsically resistant to the antibiotics and cannot promote the spread of antimicrobial resistance. Even though cases of fungemia following S. boulardii CNCM I-745 administration were reported, it should be treated as a widely available and safe probiotic strain.

show abstract

“…Thus, numerous factors predispose an individual to the development of SIBO (Table 1) (7,9,11–19,23–34). Interestingly, up to 13% of healthy individuals have also tested positive for SIBO, based on the results of breath testing or small bowel aspirate and culture (26,35–41).…”

Section: Clinical Features Prevalence and Pathoetiologymentioning

confidence: 99%

Small Intestinal Bacterial Overgrowth: Clinical Features and Therapeutic Management

Rao

Bhagatwala

2019

Clin Transl Gastroenterol

124

110

View full text Add to dashboard Cite

Small intestinal bacterial overgrowth (SIBO) is a common, yet underrecognized, problem. Its prevalence is unknown because SIBO requires diagnostic testing. Although abdominal bloating, gas, distension, and diarrhea are common symptoms, they do not predict positive diagnosis. Predisposing factors include proton-pump inhibitors, opioids, gastric bypass, colectomy, and dysmotility. Small bowel aspirate/culture with growth of 103–105 cfu/mL is generally accepted as the “best diagnostic method,” but it is invasive. Glucose or lactulose breath testing is noninvasive but an indirect method that requires further standardization and validation for SIBO. Treatment, usually with antibiotics, aims to provide symptom relief through eradication of bacteria in the small intestine. Limited numbers of controlled studies have shown systemic antibiotics (norfloxacin and metronidazole) to be efficacious. However, 15 studies have shown rifaximin, a nonsystemic antibiotic, to be effective against SIBO and well tolerated. Through improved awareness and scientific rigor, the SIBO landscape is poised for transformation.

show abstract

Prevalence of Small Intestinal Bacterial Overgrowth in Multiple Sclerosis: a Case-Control Study from China

Cited by 14 publications

References 28 publications

Impact of Body Mass Index on the Age of Relapsing-Remitting Multiple Sclerosis Onset: A Retrospective Study

Impact of Body Mass Index on the Age of Relapsing-Remitting Multiple Sclerosis Onset: A Retrospective Study

Saccharomyces boulardii CNCM I-745: A Non-bacterial Microorganism Used as Probiotic Agent in Supporting Treatment of Selected Diseases

Small Intestinal Bacterial Overgrowth: Clinical Features and Therapeutic Management

Contact Info

Product

Resources

About